BC Platforms Announces $20 Million Growth Financing led by Jolt Capital
Investment to Underpin Position as Europe’s Leading Real World Data Provider and Enabler of Personalized Precision Medicine
ZURICH, Switzerland, November 08, 2022 / B3C newswire / — BC Platforms (BCP), a global leader in healthcare data management and analytics, announced it had closed a CHF 20 million (approx. USD 20 million) financing round. New investor Jolt Capital (HQ Paris) led this growth equity financing, a fully independent private equity firm specializing in growth capital deeptech investing in Europe.
The new financing will help accelerate the expansion of the company’s data footprint, consolidating the company’s position as the leading European data provider, and enabler of personalized precision medicine, with a focus on sourcing clinically valuable Real-World Data (RWD) from European and Asian countries. The goal is to provide users of BCP’s services, which include over ten of the world’s largest pharmaceutical companies, with over 100 million accessible subjects by 2026.
The financing will also accelerate the technology leadership of the company’s platform concerning data privacy, data harmonizing functionalities, and federated machine learning (AI), which can rapidly deliver powerful insights to life science researchers and clinicians. BCP’s services boost the speed of drug development, specifically around providing high-value healthcare data that accelerate the industry’s research innovation, providing impactful R&D insights to bring more effective drugs to market more quickly, enabling affordable treatment developments for rare diseases. A major part of this core expertise includes BCP’s ‘Trusted Collaboration Environment’ (TCE). The financing will also be used to invest in BCP’s R&D coverage and grow its global sales and marketing operations. The company is already present in the US, the UK, Finland, Switzerland, and Singapore.
Tero Silvola, CEO of BCP, said, “Jolt Capital is the reference investor for European deeptech equity. We are delighted that they have recognized us as a leader in our space. This significant investment boosts our mission to become Europe’s leading data provider, focusing on high-quality RWD from multiple countries across several continents. More diverse patient data means better outcomes for patients, researchers, and society, as diagnostics and medicines are developed with the widest and fastest possible applicability. We will also be looking to build synergistic capabilities through future acquisitions.”
Laurent Samama, the Managing Partner at Jolt Capital, said, “As we are used to scaling responsible deeptech companies from Europe, we saw the phenomenal power in BCP’s genomic data discovery and analytics platforms. Access to diverse and unique patient data, and samples, is becoming fundamental to the success of biotech and pharma companies and the world’s future health. This is a considerable and fast-growing market where BCP is on track to emerge as a global leader.”
TCE is a collaboration-optimized environment created to ensure that healthcare organizations can share data with researchers globally while adhering to their local regulatory and privacy requirements. BCP has designed TCE to level the regulatory playing field for access to real-world data. It protects proprietary algorithms that support artificial intelligence and machine learning approaches for better pattern recognition. As a result, TCE ensures that the developers of new medicines can focus on their research. As BCP originates from within Europe, it fundamentally understands European data privacy, and its unique data collection technology provides significant compliance advantages for drug developers. For more about BCP’s TCE services, check online here.
About BC Platforms
BC Platforms is a global leader in building data networks for the life sciences industry and provides versatile technology platforms for personalized medicine, accelerating the translation of innovations into clinical practice. We convert complex biological information collected in the healthcare setting into actionable insights. Our innovative technology creates a patient-centric infinity loop between the life sciences and healthcare sectors. Data we generate, harmonize, and manage from diverse biobanks and healthcare institutions, is made accessible for pharmaceutical and biotech companies to enhance their core strengths in research and development. In parallel, we enable the stratification of patients towards targeted therapies, delivering on the promise of more personalized healthcare.
Our high-performing genomic data discovery and analytics platform enable flexible data integration, secure analysis, and molecular and clinical information interpretation. We have developed a Global Data Partner Network, BCRQUEST.com, which allows access to high-quality, real-world data. This rapidly growing network has a footprint across many sites, including networks of major hospitals, covering 20 countries on five continents, providing a standard of care data for over 23 million patients. Our platforms seamlessly facilitate access to highly enriched pharmaceutical research and development data.
Founded in 1997 from an MIT Whitehead project spinoff, we have a strong scientific heritage underpinned by over 25 years of working closely with a network of leading researchers, developers, and industry partners. We have global operations with our headquarters in Zurich, Switzerland, R&D in Espoo, Finland, and Singapore, as well as a presence in London and Boston. For more information, visit our website and follow us on LinkedIn.
About Jolt Capital
Jolt Capital is an independent private equity firm specializing in growth investing in advanced technology companies, with a mission to build future European leaders with a global focus. Since 2011, Jolt Capital has invested in European B2B companies with revenues between €10M and €50M. Jolt Capital’s team comprises experienced investors and managers of high-tech companies. Its proprietary AI platform, Jolt. Ninja enables enriched sourcing, accelerated due diligence, and automatic detection of investment or acquisition targets. Jolt Capital is in Paris, Lausanne, Copenhagen, and Milan.